February 12, 2025 – Alimentiv Inc. (“Alimentiv”) is pleased to announce multiple presentations and posters at the 20th Congress of ECCO (European Crohn’s and Colitis Organisation) taking place February 19-22, 2025, at the City Cube Messe Berlin, in Berlin, Germany.

Key highlights:

Dr. Vipul Jairath, Principal Investigator for the VERDICT study, will be presenting several updates on the ongoing trial, including:

  • Change in histological inflammation in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial
  • Improvement in biomarkers in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial
  • Target achievement after 48 weeks of vedolizumab treatment in patients with moderate to severe ulcerative colitis: an interim analysis from the VERDICT trial

The VERDICT trial, in collaboration with Takeda outlines a treatment approach for ulcerative colitis (UC) that prioritizes the early use of vedolizumab and achieves a specific target (either endoscopic remission, histo-endoscopic mucosal improvement, or symptomatic remission), without the need for corticosteroids. The primary aim is to determine if a treatment target of corticosteroid-free symptomatic, endoscopic, and histologic remission is better than achieving only corticosteroid-free symptomatic remission in patients with moderate-to-severely active UC. The research also aims to find specific biomarkers that can help predict which patients will benefit most from the drug and who might need alternative treatments. The phase 4 study successfully completed recruitment of 672 patients on May 6, 2024 and participants were randomized across 65 sites in 10 countries. The study is expected to be completed in 2026.

Presentations and posters

Change in histological inflammation in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial | Poster DOP007 | Presenter: Dr. Vipul Jairath

Improvement in biomarkers in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial | Poster DOP094 | Presenter: Dr. Vipul Jairath

Target achievement after 48 weeks of vedolizumab treatment in patients with moderate to severe ulcerative colitis: an interim analysis from the VERDICT trial | Poster DOP050 | Presenter: Dr. Vipul Jairath

Reliability of magnetic resonance imaging indices for evaluating perianal fistulizing disease activity in paediatric Crohn’s disease | Poster P0238 | Presenter: Dr. Eileen Crowley

Paediatric inflammatory bowel diseases: novel agents on the therapeutic horizon | Poster P0842 | Presenter: Dr. Eileen Crowley

Prevalence of immune-mediated extraintestinal manifestations in paediatric inflammatory bowel disease: a systematic review and meta-analysis | Poster P1284 | Presenter: Dr. Eileen Crowley

Placebo rates in randomised clinical trials of Ulcerative Colitis: An individual patient data meta-analysis | Poster P0541 | Presenter: Dr. Virginia Solitano

A systematic review and quality assessment of clinical practice nursing guidelines for ostomy care | Poster P0935 | Presenter: Dr. Vipul Jairath

Development, internal, and external validation of a novel endoscopic activity score for evaluation of Crohn’s disease (EASE-CD) | Poster P0390 | Presenter: Dr. Christopher Ma

Improving efficiency in early phase clinical trials for inflammatory bowel disease through use of external control arms | Poster P0831 | Presenter: Dr. Blue Neustifter

See the full schedule: https://alimentiv.com/ecco-25-poster-presentations/

Connect with Alimentiv’s experts at booth #29 and discover how we can help you achieve your project goals.

About Alimentiv Inc.

Alimentiv is a leading specialty GI-focused CRO, advancing frontiers of gastrointestinal (GI) clinical trials and medical research since 1986. As a global CRO offering clinical, medical imaging and precision medicine services, Alimentiv partners with pharmaceutical and biotechnology industries to advance the development of novel therapies and accelerate their time to market. Alimentiv is headquartered in London, Ontario, Canada, with a global footprint across its operations in Canada, the United States, Europe, Asia-Pacific, and Latin America.